Company Filing History:
Years Active: 2018-2022
Title: Innovations of Inventor Li Cheng
Introduction
Li Cheng is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules for therapeutic applications. With a total of 4 patents to his name, his work has the potential to impact cancer treatment significantly.
Latest Patents
One of Li Cheng's latest patents focuses on "Binding molecules specific for CD73 and uses thereof." This patent provides anti-CD73 binding molecules, including antibodies and their antigen-binding fragments. The disclosed compositions are designed for pharmaceutical formulations and methods aimed at diagnosing and treating diseases associated with CD73 expression, such as cancer. The treatment methods include direct therapy with the anti-CD73 binding molecules, adjuvant therapy with other anticancer agents, and combination therapies with chemotherapy.
Career Highlights
Li Cheng is currently employed at MedImmune Limited, where he continues to innovate in the field of biopharmaceuticals. His work at MedImmune has allowed him to collaborate with other experts in the field, enhancing the development of new therapeutic solutions.
Collaborations
Some of Li Cheng's coworkers include Carl Hay and Kris Sachsenmeier, who contribute to the collaborative environment at MedImmune Limited. Their combined expertise fosters innovation and drives the development of groundbreaking therapies.
Conclusion
Li Cheng's contributions to the field of biotechnology, particularly through his patents related to CD73 binding molecules, highlight his role as an influential inventor. His work at MedImmune Limited exemplifies the impact of collaboration in advancing medical science.